You are here

Roche

Roche sees a slight dip in Q1 as biosimilars keep biting into blockbuster oncology trio's sales

Roche sees a slight dip in Q1 as biosimilars keep biting into blockbuster oncology trio's sales

Endpoints

Flag link:

Roche culls 2 COVID-19 drug hopefuls amid Q1 clear-out

Roche culls 2 COVID-19 drug hopefuls amid Q1 clear-out

Fierce Biotech

Flag link:

Looking to cement its lead in packed MS market, Roche's Ocrevus uncorks new data in early-stage patients

Looking to cement its lead in packed MS market, Roche's Ocrevus uncorks new data in early-stage patients

Endpoints

multiple sclerosis

clinical trials

Flag link:

6 medtechs to watch when earnings kick off next week

6 medtechs to watch when earnings kick off next week

Medtech Dive

Edwards Lifesciences

Intuitive Surgical

Quest Diagnostics

Flag link:

Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med Actemra

Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med Actemra

Fierce Pharma

Flag link:

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

Pharmaforum

Flag link:

Senti Biosciences in $645M Spark pact to drive gene circuits into the fast lane

Senti Biosciences in $645M Spark pact to drive gene circuits into the fast lane

Fierce Biotech

Spark Therapeutics

Senti Biosciences

Flag link:

5 takeaways from AACR, one of the year's top meetings on cancer drugs

5 takeaways from AACR, one of the year's top meetings on cancer drugs

BioPharma Dive

Bristol Myers Squibb

Flag link:

Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking

Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking

Fierce Pharma

pharma industry

Bristol Myers Squibb

Flag link:

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Fierce Pharma

Flag link:

Go or no go? The FDA plays hardball

Go or no go? The FDA plays hardball

EP Vantage

Bristol Myers Squibb

accelerated approvals

Flag link:

Why Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move

Why Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move

Motley Fool

Flag link:

Regeneron and Roche's antibody cocktail shown helping in COVID-19 cases

Regeneron and Roche's antibody cocktail shown helping in COVID-19 cases

Reuters

clincial trials

Flag link:

Roche cuts bait on late-stage study of Huntington's med tominersen, an Ionis import with prior safety flags

Roche cuts bait on late-stage study of Huntington's med tominersen, an Ionis import with prior safety flags

Endpoints

Huntington's disease

Flag link:

Roche's Tecentriq is the first I-O drug to claim a post-surgery win in lung cancer. But will doctors use it?

Roche's Tecentriq is the first I-O drug to claim a post-surgery win in lung cancer. But will doctors use it?

Fierce Pharma

non-small cell lung cancer

Flag link:

Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll

Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll

Fierce Pharma

Horizon Therapeutics

employee satisfaction

Flag link:

Potential False Results with Roche Molecular Systems’ SARS-CoV-2 Assay

Potential False Results with Roche Molecular Systems’ SARS-CoV-2 Assay

FDA Law Blog

Roche Molecular Systems

Flag link:

Roche launches test to monitor emerging coronavirus variants

Roche launches test to monitor emerging coronavirus variants

Pharmaforum

COVID-19 variants

Flag link:

Roche drops $1.85B for GenMark's testing tech as pandemic, antibiotic resistance threats loom

Roche drops $1.85B for GenMark's testing tech as pandemic, antibiotic resistance threats loom

Endpoints

GenMark Diagnostics

Flag link:

GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts

GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts

Fierce Pharma

Flag link:

Pages